I hereby certify that this correction is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Box SEQUENCE

Attorney Docket No.: 15270-001430US Client Docket No.: 120-PCT-CIP1

APR 0 3 2001 EV

0 (1

TOWNSEND and TOWNSEND and CREW LL

By: Ayrda Robioch

Assistant Commissioner for Patents

Washington, D.C. 20231

RECEIVED

APR 1 0 2001

TECH CENTER 1600/290

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Mary M. Bendig et al.

Application No.: 09/155,739

Filed: September 11, 1998

For: THERAPEUTIC USES OF

Assistant Commissioner for Patents

HUMANIZED ANTIBODIES AGAINST

ALPHA-4 INTEGRIN

Box SEQUENCE

Washington, D.C. 20231

Examiner:

Gambel, P.

Art Unit:

1644

COMMUNICATION UNDER

37 C.F.R. § 1.821(e)

RECEIVED

APR 0 6 2001

OFFICE OF PETITIONS

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, mailed June 5, 2000, Applicants submit that the computer-readable form in the instant application is equivalent to the corrected sequence listing filed on August 25, 1994, in Application No. 08/186,269, filed January 25, 1994, Attorney Docket No. 015270-001400US.

In accordance with 37 C.F.R. § 1.821(e), please use the acceptable computer-readable form filed in Application No. 08/186,269 as the computer-readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary changes in application number and filing date for the computer-readable form that

Mary M. Bendig et. Application No.: 08/180,269

Page 2

will be used for the instant application. A paper copy of the sequence listing was included in the originally-filed specification of the instant application.

REMARKS

The information contained in the computer readable disk of Application No. 08/186,269 was prepared through the use of the software program "PatentIn" and was identical to that of the paper copy.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,

Andrew T. Serafini, Ph.D.

Reg. No. 41,303

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8th Floor

San Francisco, California 94111-3834

Tel: (415) 576-0200 Fax: (415) 576-0300

ATS:nsc

PA 3079259 v1